KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation

Brief description of study

This study will focus on two types of cancer: non-small cell lung cancer and colorectal cancer. The purpose of the study is to find out if a drug called JDQ443 (a type of experimental, oral drug that can target a specific protein called KRASG12C) is safe and effective for treating solid tumors with a specific genetic mutation called KRAS G12C. They will test JDQ443 with other treatments in adult patients. The study has two parts: Phase Ib and Phase II. In Phase Ib, they will test different doses of JDQ443 with other treatments to see what combination of treatments works best and what doses of the treatments have few side effects. In Phase II, they will test the dose that is most effective of JDQ443 with other treatments to see how well it works to fight cancer and if it has few side effects for patients.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.